{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-030212","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.939896+00:00","generated_at":"2026-06-11T03:33:01.348548+00:00","sec_items":["2.03","1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AgeX Therapeutics draws $500k under secured note with Juvenescence","bullets":["Drew $500,000 under Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited on August 22, 2023.","Repayment date for outstanding principal is February 14, 2024.","Terms previously summarized in May 12, 2023 10-Q and June 8, August 4, 2023 8-K filings."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-030212","json":"https://secwatch.observer/filing/0001493152-23-030212.json","markdown":"https://secwatch.observer/filing/0001493152-23-030212.md","text":"https://secwatch.observer/filing/0001493152-23-030212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223030212/0001493152-23-030212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223030212/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T03:33:01.348548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64bdd6d6341879e79b21e4cd0f0dfd4b8020b659","claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On August 22, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited. The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223030212/0001493152-23-030212-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Maturity","value":"February 14, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}